View ValuationGivaudan 将来の成長Future 基準チェック /26Givaudan利益と収益がそれぞれ年間5.4%と3.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に22.3% 5.1%なると予測されています。主要情報5.4%収益成長率5.07%EPS成長率Chemicals 収益成長39.3%収益成長率3.9%将来の株主資本利益率22.27%アナリストカバレッジGood最終更新日13 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 22Givaudan SA, Annual General Meeting, Mar 24, 2027Givaudan SA, Annual General Meeting, Mar 24, 2027.お知らせ • Apr 15Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027お知らせ • Apr 08Givaudan Active Beauty Showcases AI-Powered Ingredient Innovations With Haut.AI At In-Cosmetics GlobalGivaudan Active Beauty, the reference in high-precision beauty ingredients, has partnered with Haut.AI, to spotlight a new era of AI-driven ingredient innovation. At this year's in-cosmetics Global 2026 (April 14–16, Paris), Givaudan Active Beauty will be the first to showcase its latest active ingredients through immersive GenAI-powered activations that allow attendees to virtually "experience" their benefits firsthand via personalized, photorealistic simulations powered by Haut.AI's SkinGPT technology. As the beauty industry accelerates toward measurable efficacy, personalization, and clinically validated claims, artificial intelligence is becoming a critical bridge between laboratory science and visible consumer outcomes. In this spirit, Givaudan has selected Haut.AI's scientifically grounded skin analysis and SkinGPT simulation technologies to deliver an interactive, ingredient-focused experience at one of the industry's most influential global stages. Building on this collaboration, Givaudan Active Beauty's latest active ingredient will serve as the foundation for an interactive SkinGPT-powered virtual try-on experience at the Givaudan booth in Paris. By taking a selfie of their own face, attendees will be able to digitally "apply" the ingredient and visualize how it may influence visible skin parameters over time through a photorealistic simulation. Meanwhile they will be able to experience an AI Skin Expert analyzing their skin and delivering personalized recommendations of high precision beauty ingredients. Givaudan Active Beauty's latest breakthrough, PrimalHyal™ NeuroYouth targets the newly identified Neuro Skin Ageing pathway, supporting nerve fiber regeneration and neuronal function. By integrating AI-powered validation and immersive simulations at booth at in-cosmetics Global, the company will share this innovation in a way that allows both customers and consumers to truly experience it. Visitors to the Givaudan Active Beauty booth will be invited to engage with two AI-powered experiences: SkinGPT: At in-cosmetics Global 2026, Givaudan will unveil its latest active ingredient in an immersive experience. For the first time, attendees will be able to literally try on the formulation on their own skin through a live facial scan, instantly visualizing how it may transform visible skin parameters over time. AI Skin Expert: An on-site skin assessment providing participants with comprehensive skin insights and active ingredient recommendations aligned with their unique skin characteristics.Upcoming Dividend • Mar 16Upcoming dividend of CHF72.00 per shareEligible shareholders must have bought the stock before 23 March 2026. Payment date: 25 March 2026. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.1%).お知らせ • Feb 23Givaudan SA, Annual General Meeting, Mar 19, 2026Givaudan SA, Annual General Meeting, Mar 19, 2026, at 10:30 W. Europe Standard Time.Declared Dividend • Feb 01Dividend increased to CHF72.00Dividend of CHF72.00 is 2.9% higher than last year. Ex-date: 23rd March 2026 Payment date: 25th March 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (55% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024)Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Jan 30Givaudan SA announces Annual dividend, payable on March 25, 2026Givaudan SA announced Annual dividend of CHF 72.0000 per share payable on March 25, 2026, ex-date on March 23, 2026 and record date on March 24, 2026.お知らせ • Nov 08Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026お知らせ • Aug 28Givaudan SA Announces CEO ChangesGivaudan SA announced that Christian Stammkoetter would succeed its Chief Executive Officer, Gilles Andrier, who will retire after 20 years at the helm of the company. Stammkoetter-- who is currently president of Asia, Middle East and Africa at the French food company Danone--would take over the role effective March 1. Andrier will be proposed for election as chairman at the 2026 annual general meeting as Calvin Grieder is set to step down from the board after 12 years.Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024)First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 10Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026Upcoming Dividend • Mar 17Upcoming dividend of CHF70.00 per shareEligible shareholders must have bought the stock before 24 March 2025. Payment date: 26 March 2025. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (4.2%).お知らせ • Feb 24Givaudan SA, Annual General Meeting, Mar 20, 2025Givaudan SA, Annual General Meeting, Mar 20, 2025, at 10:30 W. Europe Standard Time.Declared Dividend • Feb 17Dividend increased to CHF70.00Dividend of CHF70.00 is 2.9% higher than last year. Ex-date: 24th March 2025 Payment date: 26th March 2025 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 25Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023)Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Aug 24Givaudan SA to Report Q3, 2025 Results on Oct 14, 2025Givaudan SA announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 14, 2025お知らせ • Aug 23Givaudan SA to Report First Half, 2025 Results on Jul 22, 2025Givaudan SA announced that they will report first half, 2025 results on Jul 22, 2025Reported Earnings • Jul 24First half 2024 earnings released: EPS: CHF63.76 (vs CHF48.69 in 1H 2023)First half 2024 results: EPS: CHF63.76 (up from CHF48.69 in 1H 2023). Revenue: CHF3.74b (up 5.7% from 1H 2023). Net income: CHF588.0m (up 31% from 1H 2023). Profit margin: 16% (up from 13% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Jul 02Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a.Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a. on July 1, 2024. Givaudan plans to finance this acquisition through debt.Givaudan SA (SWX:GIVN) completed the acquisition of remaining 75% stake in B. Kolormakeup & Skincare S.p.a.Buy Or Sell Opportunity • Jul 01Now 16% overvalued after recent price riseOver the last 90 days, the stock has risen 7.1% to CHF4,302. The fair value is estimated to be CHF3,712, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.Buy Or Sell Opportunity • Jun 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.7% to CHF4,322. The fair value is estimated to be CHF3,564, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.お知らせ • Apr 12Givaudan SA to Report Fiscal Year 2024 Results on Jan 24, 2025Givaudan SA announced that they will report fiscal year 2024 results on Jan 24, 2025Upcoming Dividend • Mar 18Upcoming dividend of CHF68.00 per shareEligible shareholders must have bought the stock before 25 March 2024. Payment date: 27 March 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (3.0%).お知らせ • Feb 08Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) .Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) on February 6, 2024. The acquisition will be 100% funded by the External Growth Credit Line contracted by Groupe Berkem. The transaction is expected to be closed on May 31, 2024. Oghma Partners acted as exclusive corporate finance advisor to Givaudan S.A.Declared Dividend • Jan 28Dividend increased to CHF68.00Dividend of CHF68.00 is 1.5% higher than last year. Ex-date: 25th March 2024 Payment date: 27th March 2024 Dividend yield will be 1.9%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 6.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 23% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 26Full year 2023 earnings released: EPS: CHF96.81 (vs CHF92.83 in FY 2022)Full year 2023 results: EPS: CHF96.81 (up from CHF92.83 in FY 2022). Revenue: CHF6.92b (down 2.8% from FY 2022). Net income: CHF893.0m (up 4.3% from FY 2022). Profit margin: 13% (in line with FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Oct 19Givaudan SA to Report First Half, 2024 Results on Jul 23, 2024Givaudan SA announced that they will report first half, 2024 results on Jul 23, 2024お知らせ • Oct 17Givaudan SA, Annual General Meeting, Mar 21, 2024Givaudan SA, Annual General Meeting, Mar 21, 2024.Reported Earnings • Jul 21First half 2023 earnings released: EPS: CHF48.69 (vs CHF47.74 in 1H 2022)First half 2023 results: EPS: CHF48.69 (up from CHF47.74 in 1H 2022). Revenue: CHF3.54b (down 3.2% from 1H 2022). Net income: CHF449.0m (up 2.0% from 1H 2022). Profit margin: 13% (in line with 1H 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).Reported Earnings • Jan 26Full year 2022 earnings released: EPS: CHF92.83 (vs CHF89.03 in FY 2021)Full year 2022 results: EPS: CHF92.83 (up from CHF89.03 in FY 2021). Revenue: CHF7.12b (up 6.5% from FY 2021). Net income: CHF856.0m (up 4.3% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Jan 25Givaudan SA to Report Fiscal Year 2023 Results on Jan 25, 2024Givaudan SA announced that they will report fiscal year 2023 results on Jan 25, 2024お知らせ • Oct 12Givaudan SA to Report Q2, 2022 Results on Jul 20, 2023Givaudan SA announced that they will report Q2, 2022 results at 7:00 AM, Central European Standard Time on Jul 20, 2023Reported Earnings • Jul 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CHF481.0m from profit in 1H 2021). Profit margin: (down from 14% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.8% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.お知らせ • Jul 22Givaudan SA to Report Fiscal Year 2022 Results on Jan 25, 2023Givaudan SA announced that they will report fiscal year 2022 results on Jan 25, 2023Upcoming Dividend • Mar 21Upcoming dividend of CHF66.00 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 74% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.6%). Lower than average of industry peers (2.6%).お知らせ • Feb 16Givaudan SA, Annual General Meeting, Mar 23, 2023Givaudan SA, Annual General Meeting, Mar 23, 2023.Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 24First half 2021 earnings released: EPS CHF52.19 (vs CHF44.81 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF3.37b (up 4.7% from 1H 2020). Net income: CHF481.0m (up 17% from 1H 2020). Profit margin: 14% (up from 13% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Mar 22Upcoming Dividend of CHF64.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 1.8% is below the top quartile of British dividend payers (4.4%), but is in line with industry peers (1.7%).Is New 90 Day High Low • Feb 23New 90-day low: CHF3,511The company is down 2.0% from its price of CHF3,585 on 25 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,220 per share.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CHF2,995, the stock is trading at a trailing P/E ratio of 44.3x, down from the previous P/E ratio of 55.1x. This compares to an average P/E of 41x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 53%.Is New 90 Day High Low • Feb 05New 90-day low: CHF2,995The company is down 24% from its price of CHF3,930 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,872 per share.Analyst Estimate Surprise Post Earnings • Feb 03Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 3.6% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Analyst Estimate Surprise Post Earnings • Feb 02Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 4.3% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Analyst Estimate Surprise Post Earnings • Jan 31Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Jan 30Full year 2020 earnings released: EPS CHF80.59 (vs CHF76.17 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF6.32b (up 1.9% from FY 2019). Net income: CHF743.0m (up 5.8% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Dec 04New 90-day low: CHF3,551The company is down 7.0% from its price of CHF3,810 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,941 per share.Is New 90 Day High Low • Nov 11New 90-day low: CHF3,672The company is down 4.0% from its price of CHF3,813 on 13 August 2020. The British market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,050 per share.Is New 90 Day High Low • Oct 05New 90-day high: CHF4,078The company is up 15% from its price of CHF3,541 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,996 per share.業績と収益の成長予測LSE:0QPS - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20288,2481,2471,1831,6771312/31/20277,8901,1711,1511,5951812/31/20267,5381,0641,0591,5151712/31/20257,4721,0711,2111,512N/A9/30/20257,5061,0831,1631,479N/A6/30/20257,5391,0941,1141,446N/A3/31/20257,4761,0921,2231,536N/A12/31/20247,4121,0901,3321,625N/A9/30/20247,2651,0611,3491,543N/A6/30/20247,1171,0321,3661,460N/A3/31/20247,0169631,2321,417N/A12/31/20236,9158931,0981,373N/A9/30/20236,9588799011,265N/A6/30/20237,0008657041,157N/A3/31/20237,0598616741,053N/A12/31/20227,117856644948N/A9/30/20227,040818676976N/A6/30/20226,9637807081,004N/A3/31/20226,8248018701,146N/A12/31/20216,6848211,0321,288N/A9/30/20216,5798161,0191,252N/A6/30/20216,4748111,0061,215N/A3/31/20216,3987779851,202N/A12/31/20206,3227439641,189N/A9/30/20206,3267399571,222N/A6/30/20206,3307359491,254N/A3/31/20206,2677198831,195N/A12/31/20196,2037028161,136N/A9/30/20196,075687N/A1,027N/A6/30/20195,947672N/A918N/A3/31/20195,737668N/A917N/A12/31/20185,527663N/A916N/A9/30/20185,385685N/A889N/A6/30/20185,242707N/A861N/A3/31/20185,147714N/A861N/A12/31/20175,051720N/A861N/A9/30/20174,932690N/A849N/A6/30/20174,812660N/A837N/A3/31/20174,738652N/A821N/A12/31/20164,663644N/A805N/A9/30/20164,605648N/A808N/A6/30/20164,546651N/A811N/A3/31/20164,471638N/A863N/A12/31/20154,396625N/A915N/A9/30/20154,397613N/A922N/A6/30/20154,397600N/A929N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0QPSの予測収益成長率 (年間5.4% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: 0QPSの収益 ( 5.4% ) UK市場 ( 11.5% ) よりも低い成長が予測されています。高成長収益: 0QPSの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 0QPSの収益 ( 3.9% ) UK市場 ( 4.5% ) よりも低い成長が予測されています。高い収益成長: 0QPSの収益 ( 3.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0QPSの 自己資本利益率 は、3年後には高くなると予測されています ( 22.3 %)成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 18:48終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Givaudan SA 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37 アナリスト機関Volker BosseBaader Helvea Equity ResearchKonstantin WiechertBaader Helvea Equity ResearchJames KnightBarclays34 その他のアナリストを表示
お知らせ • May 22Givaudan SA, Annual General Meeting, Mar 24, 2027Givaudan SA, Annual General Meeting, Mar 24, 2027.
お知らせ • Apr 15Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027
お知らせ • Apr 08Givaudan Active Beauty Showcases AI-Powered Ingredient Innovations With Haut.AI At In-Cosmetics GlobalGivaudan Active Beauty, the reference in high-precision beauty ingredients, has partnered with Haut.AI, to spotlight a new era of AI-driven ingredient innovation. At this year's in-cosmetics Global 2026 (April 14–16, Paris), Givaudan Active Beauty will be the first to showcase its latest active ingredients through immersive GenAI-powered activations that allow attendees to virtually "experience" their benefits firsthand via personalized, photorealistic simulations powered by Haut.AI's SkinGPT technology. As the beauty industry accelerates toward measurable efficacy, personalization, and clinically validated claims, artificial intelligence is becoming a critical bridge between laboratory science and visible consumer outcomes. In this spirit, Givaudan has selected Haut.AI's scientifically grounded skin analysis and SkinGPT simulation technologies to deliver an interactive, ingredient-focused experience at one of the industry's most influential global stages. Building on this collaboration, Givaudan Active Beauty's latest active ingredient will serve as the foundation for an interactive SkinGPT-powered virtual try-on experience at the Givaudan booth in Paris. By taking a selfie of their own face, attendees will be able to digitally "apply" the ingredient and visualize how it may influence visible skin parameters over time through a photorealistic simulation. Meanwhile they will be able to experience an AI Skin Expert analyzing their skin and delivering personalized recommendations of high precision beauty ingredients. Givaudan Active Beauty's latest breakthrough, PrimalHyal™ NeuroYouth targets the newly identified Neuro Skin Ageing pathway, supporting nerve fiber regeneration and neuronal function. By integrating AI-powered validation and immersive simulations at booth at in-cosmetics Global, the company will share this innovation in a way that allows both customers and consumers to truly experience it. Visitors to the Givaudan Active Beauty booth will be invited to engage with two AI-powered experiences: SkinGPT: At in-cosmetics Global 2026, Givaudan will unveil its latest active ingredient in an immersive experience. For the first time, attendees will be able to literally try on the formulation on their own skin through a live facial scan, instantly visualizing how it may transform visible skin parameters over time. AI Skin Expert: An on-site skin assessment providing participants with comprehensive skin insights and active ingredient recommendations aligned with their unique skin characteristics.
Upcoming Dividend • Mar 16Upcoming dividend of CHF72.00 per shareEligible shareholders must have bought the stock before 23 March 2026. Payment date: 25 March 2026. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.1%).
お知らせ • Feb 23Givaudan SA, Annual General Meeting, Mar 19, 2026Givaudan SA, Annual General Meeting, Mar 19, 2026, at 10:30 W. Europe Standard Time.
Declared Dividend • Feb 01Dividend increased to CHF72.00Dividend of CHF72.00 is 2.9% higher than last year. Ex-date: 23rd March 2026 Payment date: 25th March 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (55% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024)Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Jan 30Givaudan SA announces Annual dividend, payable on March 25, 2026Givaudan SA announced Annual dividend of CHF 72.0000 per share payable on March 25, 2026, ex-date on March 23, 2026 and record date on March 24, 2026.
お知らせ • Nov 08Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026
お知らせ • Aug 28Givaudan SA Announces CEO ChangesGivaudan SA announced that Christian Stammkoetter would succeed its Chief Executive Officer, Gilles Andrier, who will retire after 20 years at the helm of the company. Stammkoetter-- who is currently president of Asia, Middle East and Africa at the French food company Danone--would take over the role effective March 1. Andrier will be proposed for election as chairman at the 2026 annual general meeting as Calvin Grieder is set to step down from the board after 12 years.
Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024)First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 10Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026
Upcoming Dividend • Mar 17Upcoming dividend of CHF70.00 per shareEligible shareholders must have bought the stock before 24 March 2025. Payment date: 26 March 2025. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (4.2%).
お知らせ • Feb 24Givaudan SA, Annual General Meeting, Mar 20, 2025Givaudan SA, Annual General Meeting, Mar 20, 2025, at 10:30 W. Europe Standard Time.
Declared Dividend • Feb 17Dividend increased to CHF70.00Dividend of CHF70.00 is 2.9% higher than last year. Ex-date: 24th March 2025 Payment date: 26th March 2025 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 25Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023)Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Aug 24Givaudan SA to Report Q3, 2025 Results on Oct 14, 2025Givaudan SA announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 14, 2025
お知らせ • Aug 23Givaudan SA to Report First Half, 2025 Results on Jul 22, 2025Givaudan SA announced that they will report first half, 2025 results on Jul 22, 2025
Reported Earnings • Jul 24First half 2024 earnings released: EPS: CHF63.76 (vs CHF48.69 in 1H 2023)First half 2024 results: EPS: CHF63.76 (up from CHF48.69 in 1H 2023). Revenue: CHF3.74b (up 5.7% from 1H 2023). Net income: CHF588.0m (up 31% from 1H 2023). Profit margin: 16% (up from 13% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Jul 02Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a.Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a. on July 1, 2024. Givaudan plans to finance this acquisition through debt.Givaudan SA (SWX:GIVN) completed the acquisition of remaining 75% stake in B. Kolormakeup & Skincare S.p.a.
Buy Or Sell Opportunity • Jul 01Now 16% overvalued after recent price riseOver the last 90 days, the stock has risen 7.1% to CHF4,302. The fair value is estimated to be CHF3,712, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.
Buy Or Sell Opportunity • Jun 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.7% to CHF4,322. The fair value is estimated to be CHF3,564, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.
お知らせ • Apr 12Givaudan SA to Report Fiscal Year 2024 Results on Jan 24, 2025Givaudan SA announced that they will report fiscal year 2024 results on Jan 24, 2025
Upcoming Dividend • Mar 18Upcoming dividend of CHF68.00 per shareEligible shareholders must have bought the stock before 25 March 2024. Payment date: 27 March 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (3.0%).
お知らせ • Feb 08Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) .Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) on February 6, 2024. The acquisition will be 100% funded by the External Growth Credit Line contracted by Groupe Berkem. The transaction is expected to be closed on May 31, 2024. Oghma Partners acted as exclusive corporate finance advisor to Givaudan S.A.
Declared Dividend • Jan 28Dividend increased to CHF68.00Dividend of CHF68.00 is 1.5% higher than last year. Ex-date: 25th March 2024 Payment date: 27th March 2024 Dividend yield will be 1.9%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 6.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 23% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 26Full year 2023 earnings released: EPS: CHF96.81 (vs CHF92.83 in FY 2022)Full year 2023 results: EPS: CHF96.81 (up from CHF92.83 in FY 2022). Revenue: CHF6.92b (down 2.8% from FY 2022). Net income: CHF893.0m (up 4.3% from FY 2022). Profit margin: 13% (in line with FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Oct 19Givaudan SA to Report First Half, 2024 Results on Jul 23, 2024Givaudan SA announced that they will report first half, 2024 results on Jul 23, 2024
お知らせ • Oct 17Givaudan SA, Annual General Meeting, Mar 21, 2024Givaudan SA, Annual General Meeting, Mar 21, 2024.
Reported Earnings • Jul 21First half 2023 earnings released: EPS: CHF48.69 (vs CHF47.74 in 1H 2022)First half 2023 results: EPS: CHF48.69 (up from CHF47.74 in 1H 2022). Revenue: CHF3.54b (down 3.2% from 1H 2022). Net income: CHF449.0m (up 2.0% from 1H 2022). Profit margin: 13% (in line with 1H 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).
Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).
Reported Earnings • Jan 26Full year 2022 earnings released: EPS: CHF92.83 (vs CHF89.03 in FY 2021)Full year 2022 results: EPS: CHF92.83 (up from CHF89.03 in FY 2021). Revenue: CHF7.12b (up 6.5% from FY 2021). Net income: CHF856.0m (up 4.3% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Jan 25Givaudan SA to Report Fiscal Year 2023 Results on Jan 25, 2024Givaudan SA announced that they will report fiscal year 2023 results on Jan 25, 2024
お知らせ • Oct 12Givaudan SA to Report Q2, 2022 Results on Jul 20, 2023Givaudan SA announced that they will report Q2, 2022 results at 7:00 AM, Central European Standard Time on Jul 20, 2023
Reported Earnings • Jul 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CHF481.0m from profit in 1H 2021). Profit margin: (down from 14% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.8% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.
お知らせ • Jul 22Givaudan SA to Report Fiscal Year 2022 Results on Jan 25, 2023Givaudan SA announced that they will report fiscal year 2022 results on Jan 25, 2023
Upcoming Dividend • Mar 21Upcoming dividend of CHF66.00 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 74% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.6%). Lower than average of industry peers (2.6%).
お知らせ • Feb 16Givaudan SA, Annual General Meeting, Mar 23, 2023Givaudan SA, Annual General Meeting, Mar 23, 2023.
Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 24First half 2021 earnings released: EPS CHF52.19 (vs CHF44.81 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF3.37b (up 4.7% from 1H 2020). Net income: CHF481.0m (up 17% from 1H 2020). Profit margin: 14% (up from 13% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Mar 22Upcoming Dividend of CHF64.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 1.8% is below the top quartile of British dividend payers (4.4%), but is in line with industry peers (1.7%).
Is New 90 Day High Low • Feb 23New 90-day low: CHF3,511The company is down 2.0% from its price of CHF3,585 on 25 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,220 per share.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CHF2,995, the stock is trading at a trailing P/E ratio of 44.3x, down from the previous P/E ratio of 55.1x. This compares to an average P/E of 41x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 53%.
Is New 90 Day High Low • Feb 05New 90-day low: CHF2,995The company is down 24% from its price of CHF3,930 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,872 per share.
Analyst Estimate Surprise Post Earnings • Feb 03Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 3.6% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Analyst Estimate Surprise Post Earnings • Feb 02Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 4.3% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Analyst Estimate Surprise Post Earnings • Jan 31Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Jan 30Full year 2020 earnings released: EPS CHF80.59 (vs CHF76.17 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF6.32b (up 1.9% from FY 2019). Net income: CHF743.0m (up 5.8% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Dec 04New 90-day low: CHF3,551The company is down 7.0% from its price of CHF3,810 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,941 per share.
Is New 90 Day High Low • Nov 11New 90-day low: CHF3,672The company is down 4.0% from its price of CHF3,813 on 13 August 2020. The British market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,050 per share.
Is New 90 Day High Low • Oct 05New 90-day high: CHF4,078The company is up 15% from its price of CHF3,541 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,996 per share.